Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.

@article{Tonra2009PrioritizationOE,
  title={Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.},
  author={James R. Tonra and Erik M Corcoran and Dhanvanthri S Deevi and Philipp Steiner and Jessica A. Kearney and Huiling Li and Dale L. Ludwig and Zhenping Zhu and Larry Witte and David Surguladze and Daniel J. Hicklin},
  journal={Anticancer research},
  year={2009},
  volume={29 6},
  pages={1999-2007}
}
BACKGROUND Rational strategies utilizing anticancer efficacy and biological principles are needed for the prioritization of specific combination targeted therapy approaches for clinical development, from among the many with experimental support. MATERIALS AND METHODS Antibodies targeting epidermal growth factor receptor (EGFR) (cetuximab), insulin-like growth factor-1 receptor (IGF-IR) (IMC-A12) or vascular endothelial growth factor receptor 2 (VEGFR2) (DC101), were dosed alone or in… CONTINUE READING